<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641676</url>
  </required_header>
  <id_info>
    <org_study_id>BSMO2020-1</org_study_id>
    <nct_id>NCT04641676</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center</brief_title>
  <official_title>A Study to Examine the Value of Broad Agnostic NGS Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Belgian Society of Medical Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation Medicine</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sciensano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Belgian Society of Medical Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title of the study A study to examine the value of broad agnostic NGS panel testing versus&#xD;
      reimbursed organ-directed NGS: a Belgian Precision study of the BSMO in collaboration with&#xD;
      the Cancer Centre Study Number BSMO 2020-1 Study Phase Exploratory Sponsor Belgian Society of&#xD;
      medical Oncology (BSMO) Treatment None Background and Rationale Several drugs targeting&#xD;
      mutated gene products in cancer cells are available to Belgian patients through reimbursement&#xD;
      of the drugs and, soon, by reimbursed organ-specific genomic testing.&#xD;
&#xD;
      This context is unfavorable with regard to the following issues:&#xD;
&#xD;
        1. Many more additional drugs with sound scientific rationale and preclinical evidence are&#xD;
           available through clinical trials. The relevant genes are generally not included in the&#xD;
           reimbursed NGS and ad hoc identification of such patients is extremely difficult and&#xD;
           thus severely hampering the accrual in such trials. This denies patients a potential&#xD;
           access to innovative treatments from which they could benefit and hampers progress.&#xD;
&#xD;
        2. The same genes can be mutated in other cancer types, other than the reimbursed context,&#xD;
           but are not detected due to the organ-specific approach in reimbursed NGS. Examination&#xD;
           of these genes with an agnostic approach would give these other patients potential&#xD;
           access to the drugs (via various routes, including clinical trials or medical need or&#xD;
           otherwise)&#xD;
&#xD;
        3. The broader panels applied by some Belgian platforms (50-100 genes), sometimes in an&#xD;
           agnostic approach, do not cover all potentially actionable genes or not all types of&#xD;
           actionable variants in these genes.&#xD;
&#xD;
        4. Rearrangements which are highly actionable are not systematically covered in NGS&#xD;
           testing, but rely on immunohistochemistry (if done at all) of fusion panels testing that&#xD;
           requires additional funding.&#xD;
&#xD;
        5. The various Belgian NGS labs use accredited but heterogeneous methodology and it has&#xD;
           been reported that the detection rate of some mutations varies from one site to another.&#xD;
&#xD;
      Therefore, from a patient and oncologist point of view there are current deficiencies that&#xD;
      jeopardize optimal access of patients to current or novel genome-driven therapies. Defective&#xD;
      identification of sensitive patients limits the implementation of clinical trials and their&#xD;
      accrual rates and therefore the attractiveness of Belgium for such trials.&#xD;
&#xD;
      There are more comprehensive commercial platforms that cover a large set of actionable genes&#xD;
      (up to hundreds of genes) and the various types of mutations in these genes: sequence&#xD;
      mutations, rearrangements, resulting in fusion genes, and gene amplifications.&#xD;
&#xD;
      These commercial vendors have adequate comprehensive methodology but are too expensive (at&#xD;
      their current public pricing) for general application. One of these is the platform of&#xD;
      Foundation Medicine that builds on a large experience in variant annotation in the US and&#xD;
      includes probably all current actionable targets including gene mutations, fusions, MSI, and&#xD;
      TMB, all at once in one result. They also report actionability and established or clinical&#xD;
      trial treatment options.&#xD;
&#xD;
      To oncologists this is very attractive compared to the fragmented, sequential and very&#xD;
      limited current reimbursed conditions.&#xD;
&#xD;
      The investigators estimate that up to 20% of advanced cancer patients could get access to&#xD;
      genotype-based treatment that are not covered by the organ-based reimbursement based access&#xD;
      to NGS. This can be in the form of off-label application of reimbursed drugs,&#xD;
      pharma-sponsored drug development trials that address a specific genotype or pharma sponsored&#xD;
      or academic basket trials. Without broad agnostic testing the identification of eligible&#xD;
      patients remains extremely difficult. A recent study [A study of genetic characteristics and&#xD;
      suitability for targeted cancer treatment (TARGET)] showed that the rate of detection of&#xD;
      actionable mutations increased from 28% with local testing to 66% with Foundation Medicine&#xD;
      testing.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
        1. To determine the added value of comprehensive and agnostic NGS versus &quot;real-world&quot;&#xD;
           practice (&quot;real-world&quot; practice means local testing, no reimbursement for local testing&#xD;
           and/or no accessible metastatic lesion) in providing patients with advanced/metastatic&#xD;
           solid tumors access molecular guided therapy and/or immunotherapy based on genomic&#xD;
           results.&#xD;
&#xD;
        2. To describe the landscape of genomic alterations detected by reimbursed NGS&#xD;
&#xD;
        3. To describe he landscape of genomic alterations detected by comprehensive panel testing&#xD;
&#xD;
        4. To assess the technical success of comprehensive panel testing&#xD;
&#xD;
        5. To describe the uptake of treatments recommended by the molecular tumor board guided by&#xD;
           the genomic testing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number/prevalence of level 1, 2, 3 and 4 alterations as per OncoKB using comprehensive panel testing versus &quot;real-word&quot; practice in the three cohorts included.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/prevalence of alterations by type using Foundation Medicine testing. Descriptive results will also be presented by tumor type.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with successful comprehensive panel testing</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of level 1, 2, 3 and 4 alterations as per OncoKB detected using liquid biopsies.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a treatment recommandation based on a liquid biopsy</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Local Tumor Invasion</condition>
  <arm_group>
    <arm_group_label>Foundation medicine NGS in parallel with local NGS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patient will have in parallel FMI NGS test and Local reimbursed NGS test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Foundation Medicine NGS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patient will have only FMI NGS test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB Foundation Medicine NGS test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient do not have enough biopsy material or have tumor not accessible for a biopsy will have a liquid biopsy Foundation Medicine test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NGS testing</intervention_name>
    <description>NGS test will be performed</description>
    <arm_group_label>Foundation Medicine NGS</arm_group_label>
    <arm_group_label>Foundation medicine NGS in parallel with local NGS</arm_group_label>
    <arm_group_label>LB Foundation Medicine NGS test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1- Adult patients (18 years and above)&#xD;
&#xD;
          -  2- Patients with metastatic solid tumors that are candidates for systemic therapy&#xD;
             (early lines are preferred). Numbers will be capped for frequent tumor types (breast&#xD;
             cancer: 150 patients, NSCLC: 150 patients, colorectal cancer: 150 patients). There&#xD;
             will be a cohort of 200 patients with rare tumors or tumors with rare histology (Eur.&#xD;
             J. Cancer 2011; 47: 2493-2511). Patients will be recruited as they appear in clinical&#xD;
             practice.&#xD;
&#xD;
             3- Patients will be enrolled following three clinical scenarios: a) patients eligible&#xD;
             for local NGS testing (reimbursed or local practice); b) patients that are not&#xD;
             eligible for reimbursed or local NGS testing; c) patients with no sufficient archival&#xD;
             tissue meeting the pre-requirements will only undergo FMI liquid biopsy testing&#xD;
             (exploratory cohort). That last cohort will be capped at 100 patients and will not&#xD;
             have more than 50% of patients with the same tumor type.&#xD;
&#xD;
             4- Patients enrolled in scenario a) and b) must have enough tissue from a metastatic&#xD;
             (preferred) or primary lesion biopsy for local testing and FMI testing. The tissue&#xD;
             should not be more than 3 years-old and fixed in 10% neutral buffered formalin.&#xD;
             Availability of metastatic biopsies performed after a previous therapy line are&#xD;
             mandatory for patients treated with therapies that are known to induce acquired&#xD;
             mechanisms of resistance (EGFR TKIs in NSCLC, aromatase inhibitors in breast cancer,&#xD;
             TKIs in Gastrointestinal stromal tumor (GIST)…). Bone biopsies that undergo&#xD;
             decalcification are not allowed.&#xD;
&#xD;
             5- Patient showing an Eastern Cooperative Oncology Group (ECOG) Performance Status of&#xD;
             ≤ 2.&#xD;
&#xD;
             6- Patients can only be enrolled if they are also concomitantly registered in the&#xD;
             Precision 1 study and the investigator agrees to subsequent registration of&#xD;
             genotype-driven treatments given and the investigator assessed outcome on these&#xD;
             treatments (RR and PFS).&#xD;
&#xD;
             7- Patients able to provide written informed consent prior to enrollment into a&#xD;
             potential subsequent clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1- Life expectancy of less than 12 weeks.&#xD;
&#xD;
          -  2- Inability to comply with protocol procedures.&#xD;
&#xD;
          -  3- Known presence of severe hematopoietic, renal, and/or hepatic dysfunction&#xD;
             (according to the local PI).&#xD;
&#xD;
             4- - No informed consent provided.&#xD;
&#xD;
          -  5- Patient is not enrolled and followed as provided in Precision 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maïté de Hemptinne</last_name>
    <phone>+32 4 74 56 73 88</phone>
    <email>maite.dehemptinne@sciensano.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gordana Raicevic Toungouz</last_name>
    <phone>+32 4 76 97 34 06</phone>
    <email>Gordana.RaicevicToungouz@sciensano.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ZNA</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdelbari Baitar</last_name>
      <phone>+32 3 280 31 30</phone>
      <email>abdelbari.baitar@zna.be</email>
    </contact>
    <contact_backup>
      <last_name>Myriam Mertens</last_name>
      <phone>+32 3 280 31 30</phone>
      <email>myriam.mertens@zna.be</email>
    </contact_backup>
    <investigator>
      <last_name>Joanna Vermeij, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GZA</name>
      <address>
        <city>Antwerp</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jo Horemans</last_name>
      <phone>+32 3 443 37 59</phone>
      <email>jo.horemans@gza.be</email>
    </contact>
    <investigator>
      <last_name>Luc Dirix, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charis Loos</last_name>
      <phone>+32 3 650 53 99</phone>
      <email>Charis.Loos@klina.be</email>
    </contact>
    <investigator>
      <last_name>Wim Demey, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanny Bustin</last_name>
      <phone>+32 2 541 32 20</phone>
      <email>fanny.bustin@bordet.be</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie Bartholomeus</last_name>
      <phone>+32 2 541 32 20</phone>
      <email>sylvie.bartholomeus@bordet.be</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Aftimos, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Fastenaekels</last_name>
      <phone>+32 2 474 94 78</phone>
      <email>Vanessa.Fastenaekels@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Malika Tahiri</last_name>
      <phone>+32 2 474 94 78</phone>
      <email>Malika.Tahiri@uzbrussel.be</email>
    </contact_backup>
    <investigator>
      <last_name>Lore Decoster, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Les Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Decroës</last_name>
      <phone>+32 2 764 42 97</phone>
      <email>valerie.decroes@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Cédric Van Marcke de Lummen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Warnon</last_name>
      <phone>+32 71 10 47 47</phone>
      <email>Stephanie.WARNON@ghdc.be</email>
    </contact>
    <contact_backup>
      <last_name>Matthias Papier</last_name>
      <phone>+32 71 10 47 47</phone>
      <email>matthias.papier@ghdc.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Luc Canon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greet De Craen</last_name>
      <phone>+32 3 821 41 21</phone>
      <email>Greet.DeCraen@uza.be</email>
    </contact>
    <investigator>
      <last_name>Marc Peeters, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lore Vansteelant</last_name>
      <phone>+32 9 332 57 93</phone>
      <email>Lore.Vansteelant@UZGENT.be</email>
    </contact>
    <investigator>
      <last_name>Sylvie Rottey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Tullen</last_name>
      <phone>+32 11 33 79 91</phone>
      <email>ann.tullen@jessazh.be</email>
    </contact>
    <investigator>
      <last_name>Jeroen Mebis, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Schroeder</last_name>
      <phone>+3243668203</phone>
      <email>hschroeder@chuliege.be</email>
    </contact>
    <contact_backup>
      <last_name>Astrid Collinge</last_name>
      <phone>+3243668203</phone>
      <email>acollinge@chuliege.be</email>
    </contact_backup>
    <investigator>
      <last_name>Joelle Collignon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Willem Lybaert, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

